COX-2-IN-34 

COX-2-IN-34 (compound 8a) is a selective and orally active inhibitor of COX-2 , with an IC₅₀ of 0.42 μM. COX-2-IN-34 has no gastric ulcer toxicity but has anti-inflammatory effects^[1].

COX-2-IN-34 (compound 8a) (100 μM, 24 h) shows no obvious cytotoxicity to RAW264.7 cells^[1].
Cox-2- IN -34 selectively inhibits the COX-1 and COX-2 activity with IC₅₀ values of 34.86 and 0.42μM, respectively. The inhibition effect of COX-2-IN-34 (10 μM ) on COX-2 reaches 82%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

COX-2-IN-34 (compound 8a) (50 mg/kg for p.o., three days) shows no gastric ulceration in normal male rat model^[1].
COX-2-IN-34 (50 mg/kg for s.c., three times) shows significant anti-inflammatory effects in the Carrageenan-induced rat paw edema assay model ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

245.23

C₁₃H₁₁NO₄

2788578-71-0

O=C(NC1=CC=CC=C1O)C2=CC=CC(O)=C2O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. 1. 1. Min Xin, et al. Synthesis and biological evaluation of resveratrol amide derivatives as selective COX-2 inhibitors. Chemico-Biological Interactions. Volume 380, 1 August 2023, 110522.